IDO1 and neoplasm: The inhibition of IDO1 leads to metabolic adaptation that promotes the NAD+ biosynthetic pathway, which inhibits T cell proliferation and expression, and A2a and/or A2b purinergic receptor antagonists were found to block NAD+ inhibition of T cells, thereby ameliorating the metabolic adaptation induced by IDO1 inhibition and promoting tumor immunity.80